- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05766111
COVID-19 Seroprevalence Among Healthcare Workers of a Large COVID-19 Hospital in Rome
Seroprevalence Survey in Healthcare Workers of the A. Gemelli IRCCS University Hospital Foundation as Part of the Surveillance and Control Activities of the Covid-19 Epidemic
Study Overview
Status
Conditions
Detailed Description
This cross-sectional study will consist of a seroprevalence survey between June 2020 and July 2020, which enroll participants on a voluntary basis via a hospital e-mail system, including medical, non-medical HCW, and administrative staff (AS) of the FPG. The study approved by the FPG ethics committee and participants sign an informed consent form before their inclusion in the study. Both the venous blood and POC SARS-CoV-2 serological tests will offer to each participant and perform in dedicated blood-drawing areas in compliance with COVID-19 safety regulations. In cases with a positive result from at least one test, participants undergo NOS sampling for RT-PCR SARS-CoV-2 RNA detection to assess the actual infection status . Unlike the venous blood testing, the POC testing will perform by trained clinical staff composed of public health residents and student nurses.Medical and non-medical HCWs will categorize into two groups by whether they had or had not assisted COVID-19 patients in the period between 9 March 2020 (the date of the first COVID-19 patients in our hospital) and 1 June 2020 (the date of seroprevalence survey initiation). For predictivity analysis, which requires the consideration of the prevalence of the studied population, we used the AS as a further comparison group, because this was a group with low seroprevalence. This is because these participants were less exposed to COVID-19 infection than HCWs and many of them had been in work-from-home arrangements for two days a week from 9 March 2020.
As mentioned above, participants that will test positive for SARS-CoV-2 specific antibodies, with at least one of the serological tests used in the study, will sample for NOS testing within 48 h after positive serological test results will be available. RT-PCR testing on NOS samples will perform using the Seegene Allplex™ 2019-nCoV assay, and a positive result (i.e., a Ct less than 40) for at least one of two viral targets (i.e., RdRP and N genes) indicated the presence of SARS-CoV-2 RNA. As current studies show marked variation and are likely to overestimate sensitivity, we used the lower end of current estimates from systematic reviews, with the approximate numbers of 70% for sensitivity and 95% for specificity, for illustrative purposes.
Descriptive analysis will perform for sex, age, professional category, and wards of the HCWs. The difference between proportions will evaluate with the two proportion Z test. Seroprevalence will calculate, separately, for tests on the venous samples and the POC tests. Seroprevalence for the tests on the venous samples will estimate as the proportion of individuals who will have a positive result of IgG in the immunoassay. Furthermore, for the tests on capillary blood, seroprevalence for both IgM and IgG will estimete as the proportion of individuals who will have positive results in the corresponding band of the POC test.
We also re-estimate the sensitivity and specificity of the POC test using the immunoassay as a reference. The accuracy of the capillary versus the venous test will evaluate with sensitivity, specificity, and predictive values with 95% confidence intervals (CIs). Each of the seroprevalences will stratify for professional category, age, and wards in which they worked during the COVID-19 emergency.
The difference between positivity in one of the serological tests and positivity in the RT-PCR on NOS samples will estimate through Pearson's chi-squared tests. The Spearman rank test (Bonferroni-adjusted) will use to evaluate the correlation between the anti-SARS-CoV-2 IgG assay in capillary blood versus the same titer in venous blood.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
RM
-
Roma, RM, Italy, 00168
- Fondazione Policlinico Gemelli
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- employees of the Fondazione Policlinico Gemelli Hospital
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Detection of Anti-SARS-CoV-2 Antibodies in Blood Samples
Time Frame: 1 month
|
Prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based on the serological tests and stratified by age, sex, professional category, and direct assistance to COVID-19 patients or not (COVID-19 care, Yes/No)
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Detection of COVID-19 Infection among Healthcare Workers
Time Frame: 1 month
|
1 month
|
Sensitivity and Specificity of Serological Tests
Time Frame: 1 month
|
1 month
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3253
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States